 | • レポートコード：GIR-107A14647 • 出版社/出版日：GlobalInfoResearch / 2021年7月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、109ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医薬品 |
| Single User | ￥522,000 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥783,000 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,044,000 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料では、脈絡膜新生血管治療薬のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。脈絡膜新生血管治療薬の種類別市場規模（AVMOC-001、BB-3、BBT-007、DG-3、Entolimod、EWA-001、その他）、用途別市場規模（診療所、病院、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・脈絡膜新生血管治療薬の市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：Cellphire, Inc.、Chrysalis BioTherapeutics, Inc.、Cleveland BioLabs, Inc.、Cumberland Pharmaceuticals, Inc.、Diffusion Pharmaceuticals Inc.、Eli Lilly and Company、GNI Group Ltd.、Humanetics Corporation、INSYS Therapeutics, Inc.、Meabco A/S、Neumedicines Inc.、Onconova Therapeutics, Inc.、PharmaIN Corporation、Pluristem Therapeutics Inc.、ProCertus BioPharm Inc.、RDD Pharma Ltd.、RedHill Biopharma Ltd.、RxBio, Inc.、Soligenix, Inc. ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：AVMOC-001、BB-3、BBT-007、DG-3、Entolimod、EWA-001、その他 ・用途別分析2016年-2026年：診療所、病院、その他 ・脈絡膜新生血管治療薬の北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・脈絡膜新生血管治療薬のヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・脈絡膜新生血管治療薬のアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・脈絡膜新生血管治療薬の南米市場規模2016年-2026年：ブラジル、アルゼンチン ・脈絡膜新生血管治療薬の中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
The Choroidal Neovascularization Drug market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest research, the global Choroidal Neovascularization Drug size is estimated to be xx million in 2021 from USD xx million in 2020, with a change of XX% between 2020 and 2021. The global Choroidal Neovascularization Drug market size is expected to grow at a CAGR of xx% for the next five years.
Market segmentation
Choroidal Neovascularization Drug market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
AVMOC-001
BB-3
BBT-007
DG-3
Entolimod
EWA-001
Others
Market segment by Application can be divided into
Clinic
Hospital
Others
The key market players for global Choroidal Neovascularization Drug market are listed below:
Cellphire, Inc.
Chrysalis BioTherapeutics, Inc.
Cleveland BioLabs, Inc.
Cumberland Pharmaceuticals, Inc.
Diffusion Pharmaceuticals Inc.
Eli Lilly and Company
GNI Group Ltd.
Humanetics Corporation
INSYS Therapeutics, Inc.
Meabco A/S
Neumedicines Inc.
Onconova Therapeutics, Inc.
PharmaIN Corporation
Pluristem Therapeutics Inc.
ProCertus BioPharm Inc.
RDD Pharma Ltd.
RedHill Biopharma Ltd.
RxBio, Inc.
Soligenix, Inc.
Market segment by Region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 14 chapters:
Chapter 1, to describe Choroidal Neovascularization Drug product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Choroidal Neovascularization Drug, with price, sales, revenue and global market share of Choroidal Neovascularization Drug from 2019 to 2021.
Chapter 3, the Choroidal Neovascularization Drug competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Choroidal Neovascularization Drug breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2016 to 2026.
Chapter 5 and 6, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2016 to 2026.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2016 to 2021.and Choroidal Neovascularization Drug market forecast, by regions, type and application, with sales and revenue, from 2021 to 2026.
Chapter 12, 13 and 14, to describe Choroidal Neovascularization Drug sales channel, distributors, customers, research findings and conclusion, appendix and data source.
1 Market Overview
1.1 Choroidal Neovascularization Drug Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Choroidal Neovascularization Drug Revenue by Type: 2019 Versus 2021 Versus 2026
1.2.2 AVMOC-001
1.2.3 BB-3
1.2.4 BBT-007
1.2.5 DG-3
1.2.6 Entolimod
1.2.7 EWA-001
1.2.8 Others
1.3 Market Analysis by Application
1.3.1 Overview: Global Choroidal Neovascularization Drug Revenue by Application: 2019 Versus 2021 Versus 2026
1.3.2 Clinic
1.3.3 Hospital
1.3.4 Others
1.4 Global Choroidal Neovascularization Drug Market Size & Forecast
1.4.1 Global Choroidal Neovascularization Drug Sales in Value (2016-2026))
1.4.2 Global Choroidal Neovascularization Drug Sales in Volume (2016-2026)
1.4.3 Global Choroidal Neovascularization Drug Price by Type (2016-2026) & (USD/Pcs)
1.5 Global Choroidal Neovascularization Drug Production Capacity Analysis
1.5.1 Global Choroidal Neovascularization Drug Total Production Capacity (2016-2026)
1.5.2 Global Choroidal Neovascularization Drug Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Choroidal Neovascularization Drug Market Drivers
1.6.2 Choroidal Neovascularization Drug Market Restraints
1.6.3 Choroidal Neovascularization Drug Trends Analysis
2 Manufacturers Profiles
2.1 Cellphire, Inc.
2.1.1 Cellphire, Inc. Details
2.1.2 Cellphire, Inc. Major Business
2.1.3 Cellphire, Inc. Choroidal Neovascularization Drug Product and Services
2.1.4 Cellphire, Inc. Choroidal Neovascularization Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.2 Chrysalis BioTherapeutics, Inc.
2.2.1 Chrysalis BioTherapeutics, Inc. Details
2.2.2 Chrysalis BioTherapeutics, Inc. Major Business
2.2.3 Chrysalis BioTherapeutics, Inc. Choroidal Neovascularization Drug Product and Services
2.2.4 Chrysalis BioTherapeutics, Inc. Choroidal Neovascularization Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.3 Cleveland BioLabs, Inc.
2.3.1 Cleveland BioLabs, Inc. Details
2.3.2 Cleveland BioLabs, Inc. Major Business
2.3.3 Cleveland BioLabs, Inc. Choroidal Neovascularization Drug Product and Services
2.3.4 Cleveland BioLabs, Inc. Choroidal Neovascularization Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.4 Cumberland Pharmaceuticals, Inc.
2.4.1 Cumberland Pharmaceuticals, Inc. Details
2.4.2 Cumberland Pharmaceuticals, Inc. Major Business
2.4.3 Cumberland Pharmaceuticals, Inc. Choroidal Neovascularization Drug Product and Services
2.4.4 Cumberland Pharmaceuticals, Inc. Choroidal Neovascularization Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.5 Diffusion Pharmaceuticals Inc.
2.5.1 Diffusion Pharmaceuticals Inc. Details
2.5.2 Diffusion Pharmaceuticals Inc. Major Business
2.5.3 Diffusion Pharmaceuticals Inc. Choroidal Neovascularization Drug Product and Services
2.5.4 Diffusion Pharmaceuticals Inc. Choroidal Neovascularization Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.6 Eli Lilly and Company
2.6.1 Eli Lilly and Company Details
2.6.2 Eli Lilly and Company Major Business
2.6.3 Eli Lilly and Company Choroidal Neovascularization Drug Product and Services
2.6.4 Eli Lilly and Company Choroidal Neovascularization Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.7 GNI Group Ltd.
2.7.1 GNI Group Ltd. Details
2.7.2 GNI Group Ltd. Major Business
2.7.3 GNI Group Ltd. Choroidal Neovascularization Drug Product and Services
2.7.4 GNI Group Ltd. Choroidal Neovascularization Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.8 Humanetics Corporation
2.8.1 Humanetics Corporation Details
2.8.2 Humanetics Corporation Major Business
2.8.3 Humanetics Corporation Choroidal Neovascularization Drug Product and Services
2.8.4 Humanetics Corporation Choroidal Neovascularization Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.9 INSYS Therapeutics, Inc.
2.9.1 INSYS Therapeutics, Inc. Details
2.9.2 INSYS Therapeutics, Inc. Major Business
2.9.3 INSYS Therapeutics, Inc. Choroidal Neovascularization Drug Product and Services
2.9.4 INSYS Therapeutics, Inc. Choroidal Neovascularization Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.10 Meabco A/S
2.10.1 Meabco A/S Details
2.10.2 Meabco A/S Major Business
2.10.3 Meabco A/S Choroidal Neovascularization Drug Product and Services
2.10.4 Meabco A/S Choroidal Neovascularization Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.11 Neumedicines Inc.
2.11.1 Neumedicines Inc. Details
2.11.2 Neumedicines Inc. Major Business
2.11.3 Neumedicines Inc. Choroidal Neovascularization Drug Product and Services
2.11.4 Neumedicines Inc. Choroidal Neovascularization Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.12 Onconova Therapeutics, Inc.
2.12.1 Onconova Therapeutics, Inc. Details
2.12.2 Onconova Therapeutics, Inc. Major Business
2.12.3 Onconova Therapeutics, Inc. Choroidal Neovascularization Drug Product and Services
2.12.4 Onconova Therapeutics, Inc. Choroidal Neovascularization Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.13 PharmaIN Corporation
2.13.1 PharmaIN Corporation Details
2.13.2 PharmaIN Corporation Major Business
2.13.3 PharmaIN Corporation Choroidal Neovascularization Drug Product and Services
2.13.4 PharmaIN Corporation Choroidal Neovascularization Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.14 Pluristem Therapeutics Inc.
2.14.1 Pluristem Therapeutics Inc. Details
2.14.2 Pluristem Therapeutics Inc. Major Business
2.14.3 Pluristem Therapeutics Inc. Choroidal Neovascularization Drug Product and Services
2.14.4 Pluristem Therapeutics Inc. Choroidal Neovascularization Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.15 ProCertus BioPharm Inc.
2.15.1 ProCertus BioPharm Inc. Details
2.15.2 ProCertus BioPharm Inc. Major Business
2.15.3 ProCertus BioPharm Inc. Choroidal Neovascularization Drug Product and Services
2.15.4 ProCertus BioPharm Inc. Choroidal Neovascularization Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.16 RDD Pharma Ltd.
2.16.1 RDD Pharma Ltd. Details
2.16.2 RDD Pharma Ltd. Major Business
2.16.3 RDD Pharma Ltd. Choroidal Neovascularization Drug Product and Services
2.16.4 RDD Pharma Ltd. Choroidal Neovascularization Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.17 RedHill Biopharma Ltd.
2.17.1 RedHill Biopharma Ltd. Details
2.17.2 RedHill Biopharma Ltd. Major Business
2.17.3 RedHill Biopharma Ltd. Choroidal Neovascularization Drug Product and Services
2.17.4 RedHill Biopharma Ltd. Choroidal Neovascularization Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.18 RxBio, Inc.
2.18.1 RxBio, Inc. Details
2.18.2 RxBio, Inc. Major Business
2.18.3 RxBio, Inc. Choroidal Neovascularization Drug Product and Services
2.18.4 RxBio, Inc. Choroidal Neovascularization Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.19 Soligenix, Inc.
2.19.1 Soligenix, Inc. Details
2.19.2 Soligenix, Inc. Major Business
2.19.3 Soligenix, Inc. Choroidal Neovascularization Drug Product and Services
2.19.4 Soligenix, Inc. Choroidal Neovascularization Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
3 Choroidal Neovascularization Drug Sales by Manufacturer
3.1 Global Choroidal Neovascularization Drug Sales in Volume by Manufacturer (2019-2021e)
3.2 Global Choroidal Neovascularization Drug Revenue by Manufacturer (2019-2021e)
3.3 Key Manufacturer Market Position in Choroidal Neovascularization Drug
3.4 Market Concentration Rate
3.4.1 Top 3 Choroidal Neovascularization Drug Manufacturer Market Share
3.4.2 Top 6 Choroidal Neovascularization Drug Manufacturer Market Share
3.5 Global Choroidal Neovascularization Drug Production Capacity by Company
3.6 Manufacturer by Geography: Head Office and Choroidal Neovascularization Drug Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Choroidal Neovascularization Drug Market Size by Region
4.1.1 Global Choroidal Neovascularization Drug Sales in Volume by Region (2016-2026)
4.1.2 Global Choroidal Neovascularization Drug Revenue by Region (2016-2026)
4.2 North America Choroidal Neovascularization Drug Revenue (2016-2026)
4.3 Europe Choroidal Neovascularization Drug Revenue (2016-2026)
4.4 Asia-Pacific Choroidal Neovascularization Drug Revenue (2016-2026)
4.5 South America Choroidal Neovascularization Drug Revenue (2016-2026)
4.6 Middle East and Africa Choroidal Neovascularization Drug Revenue (2016-2026)
5 Market Segment by Type
5.1 Global Choroidal Neovascularization Drug Sales in Volume by Type (2016-2026)
5.2 Global Choroidal Neovascularization Drug Revenue by Type (2016-2026)
5.3 Global Choroidal Neovascularization Drug Price by Type (2016-2026)
6 Market Segment by Application
6.1 Global Choroidal Neovascularization Drug Sales in Volume by Application (2016-2026)
6.2 Global Choroidal Neovascularization Drug Revenue by Application (2016-2026)
6.3 Global Choroidal Neovascularization Drug Price by Application (2016-2026)
7 North America by Country, by Type, and by Application
7.1 North America Choroidal Neovascularization Drug Sales by Type (2016-2026)
7.2 North America Choroidal Neovascularization Drug Sales by Application (2016-2026)
7.3 North America Choroidal Neovascularization Drug Market Size by Country
7.3.1 North America Choroidal Neovascularization Drug Sales in Volume by Country (2016-2026)
7.3.2 North America Choroidal Neovascularization Drug Revenue by Country (2016-2026)
7.3.3 United States Market Size and Forecast (2016-2026)
7.3.4 Canada Market Size and Forecast (2016-2026)
7.3.5 Mexico Market Size and Forecast (2016-2026)
8 Europe by Country, by Type, and by Application
8.1 Europe Choroidal Neovascularization Drug Sales by Type (2016-2026)
8.2 Europe Choroidal Neovascularization Drug Sales by Application (2016-2026)
8.3 Europe Choroidal Neovascularization Drug Market Size by Country
8.3.1 Europe Choroidal Neovascularization Drug Sales in Volume by Country (2016-2026)
8.3.2 Europe Choroidal Neovascularization Drug Revenue by Country (2016-2026)
8.3.3 Germany Market Size and Forecast (2016-2026)
8.3.4 France Market Size and Forecast (2016-2026)
8.3.5 United Kingdom Market Size and Forecast (2016-2026)
8.3.6 Russia Market Size and Forecast (2016-2026)
8.3.7 Italy Market Size and Forecast (2016-2026)
9 Asia-Pacific by Country, by Type, and by Application
9.1 Asia-Pacific Choroidal Neovascularization Drug Sales by Type (2016-2026)
9.2 Asia-Pacific Choroidal Neovascularization Drug Sales by Application (2016-2026)
9.3 Asia-Pacific Choroidal Neovascularization Drug Market Size by Region
9.3.1 Asia-Pacific Choroidal Neovascularization Drug Sales in Volume by Region (2016-2026)
9.3.2 Asia-Pacific Choroidal Neovascularization Drug Revenue by Region (2016-2026)
9.3.3 China Market Size and Forecast (2016-2026)
9.3.4 Japan Market Size and Forecast (2016-2026)
9.3.5 Korea Market Size and Forecast (2016-2026)
9.3.6 India Market Size and Forecast (2016-2026)
9.3.7 Southeast Asia Market Size and Forecast (2016-2026)
9.3.8 Australia Market Size and Forecast (2016-2026)
10 South America by Country, by Type, and by Application
10.1 South America Choroidal Neovascularization Drug Sales by Type (2016-2026)
10.2 South America Choroidal Neovascularization Drug Sales by Application (2016-2026)
10.3 South America Choroidal Neovascularization Drug Market Size by Country
10.3.1 South America Choroidal Neovascularization Drug Sales in Volume by Country (2016-2026)
10.3.2 South America Choroidal Neovascularization Drug Revenue by Country (2016-2026)
10.3.3 Brazil Market Size and Forecast (2016-2026)
10.3.4 Argentina Market Size and Forecast (2016-2026)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Choroidal Neovascularization Drug Sales by Type (2016-2026)
11.2 Middle East & Africa Choroidal Neovascularization Drug Sales by Application (2016-2026)
11.3 Middle East & Africa Choroidal Neovascularization Drug Market Size by Country
11.3.1 Middle East & Africa Choroidal Neovascularization Drug Sales in Volume by Country (2016-2026)
11.3.2 Middle East & Africa Choroidal Neovascularization Drug Revenue by Country (2016-2026)
11.3.3 Turkey Market Size and Forecast (2016-2026)
11.3.4 Egypt Market Size and Forecast (2016-2026)
11.3.5 Saudi Arabia Market Size and Forecast (2016-2026)
11.3.6 South Africa Market Size and Forecast (2016-2026)
12 Sales Channel, Distributors, Traders and Dealers
12.1 Sales Channel
12.1.1 Direct Marketing
12.1.2 Indirect Marketing
12.2 Choroidal Neovascularization Drug Typical Distributors
12.3 Choroidal Neovascularization Drug Typical Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
Table 1. Global Choroidal Neovascularization Drug Revenue by Type, (USD Million), 2021-2026
Table 2. Global Choroidal Neovascularization Drug Revenue by Application, (USD Million), 2021-2026
Table 3. Cellphire, Inc. Basic Information, Manufacturing Base and Competitors
Table 4. Cellphire, Inc. Major Business
Table 5. Cellphire, Inc. Choroidal Neovascularization Drug Product and Services
Table 6. Cellphire, Inc. Choroidal Neovascularization Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 7. Chrysalis BioTherapeutics, Inc. Basic Information, Manufacturing Base and Competitors
Table 8. Chrysalis BioTherapeutics, Inc. Major Business
Table 9. Chrysalis BioTherapeutics, Inc. Choroidal Neovascularization Drug Product and Services
Table 10. Chrysalis BioTherapeutics, Inc. Choroidal Neovascularization Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 11. Cleveland BioLabs, Inc. Basic Information, Manufacturing Base and Competitors
Table 12. Cleveland BioLabs, Inc. Major Business
Table 13. Cleveland BioLabs, Inc. Choroidal Neovascularization Drug Product and Services
Table 14. Cleveland BioLabs, Inc. Choroidal Neovascularization Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 15. Cumberland Pharmaceuticals, Inc. Basic Information, Manufacturing Base and Competitors
Table 16. Cumberland Pharmaceuticals, Inc. Major Business
Table 17. Cumberland Pharmaceuticals, Inc. Choroidal Neovascularization Drug Product and Services
Table 18. Cumberland Pharmaceuticals, Inc. Choroidal Neovascularization Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 19. Diffusion Pharmaceuticals Inc. Basic Information, Manufacturing Base and Competitors
Table 20. Diffusion Pharmaceuticals Inc. Major Business
Table 21. Diffusion Pharmaceuticals Inc. Choroidal Neovascularization Drug Product and Services
Table 22. Diffusion Pharmaceuticals Inc. Choroidal Neovascularization Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 23. Eli Lilly and Company Basic Information, Manufacturing Base and Competitors
Table 24. Eli Lilly and Company Major Business
Table 25. Eli Lilly and Company Choroidal Neovascularization Drug Product and Services
Table 26. Eli Lilly and Company Choroidal Neovascularization Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 27. GNI Group Ltd. Basic Information, Manufacturing Base and Competitors
Table 28. GNI Group Ltd. Major Business
Table 29. GNI Group Ltd. Choroidal Neovascularization Drug Product and Services
Table 30. GNI Group Ltd. Choroidal Neovascularization Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 31. Humanetics Corporation Basic Information, Manufacturing Base and Competitors
Table 32. Humanetics Corporation Major Business
Table 33. Humanetics Corporation Choroidal Neovascularization Drug Product and Services
Table 34. Humanetics Corporation Choroidal Neovascularization Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 35. INSYS Therapeutics, Inc. Basic Information, Manufacturing Base and Competitors
Table 36. INSYS Therapeutics, Inc. Major Business
Table 37. INSYS Therapeutics, Inc. Choroidal Neovascularization Drug Product and Services
Table 38. INSYS Therapeutics, Inc. Choroidal Neovascularization Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 39. Meabco A/S Basic Information, Manufacturing Base and Competitors
Table 40. Meabco A/S Major Business
Table 41. Meabco A/S Choroidal Neovascularization Drug Product and Services
Table 42. Meabco A/S Choroidal Neovascularization Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 43. Neumedicines Inc. Basic Information, Manufacturing Base and Competitors
Table 44. Neumedicines Inc. Major Business
Table 45. Neumedicines Inc. Choroidal Neovascularization Drug Product and Services
Table 46. Neumedicines Inc. Choroidal Neovascularization Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 47. Onconova Therapeutics, Inc. Basic Information, Manufacturing Base and Competitors
Table 48. Onconova Therapeutics, Inc. Major Business
Table 49. Onconova Therapeutics, Inc. Choroidal Neovascularization Drug Product and Services
Table 50. Onconova Therapeutics, Inc. Choroidal Neovascularization Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 51. PharmaIN Corporation Basic Information, Manufacturing Base and Competitors
Table 52. PharmaIN Corporation Major Business
Table 53. PharmaIN Corporation Choroidal Neovascularization Drug Product and Services
Table 54. PharmaIN Corporation Choroidal Neovascularization Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 55. Pluristem Therapeutics Inc. Basic Information, Manufacturing Base and Competitors
Table 56. Pluristem Therapeutics Inc. Major Business
Table 57. Pluristem Therapeutics Inc. Choroidal Neovascularization Drug Product and Services
Table 58. Pluristem Therapeutics Inc. Choroidal Neovascularization Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 59. ProCertus BioPharm Inc. Basic Information, Manufacturing Base and Competitors
Table 60. ProCertus BioPharm Inc. Major Business
Table 61. ProCertus BioPharm Inc. Choroidal Neovascularization Drug Product and Services
Table 62. ProCertus BioPharm Inc. Choroidal Neovascularization Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 63. RDD Pharma Ltd. Basic Information, Manufacturing Base and Competitors
Table 64. RDD Pharma Ltd. Major Business
Table 65. RDD Pharma Ltd. Choroidal Neovascularization Drug Product and Services
Table 66. RDD Pharma Ltd. Choroidal Neovascularization Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 67. RedHill Biopharma Ltd. Basic Information, Manufacturing Base and Competitors
Table 68. RedHill Biopharma Ltd. Major Business
Table 69. RedHill Biopharma Ltd. Choroidal Neovascularization Drug Product and Services
Table 70. RedHill Biopharma Ltd. Choroidal Neovascularization Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 71. RxBio, Inc. Basic Information, Manufacturing Base and Competitors
Table 72. RxBio, Inc. Major Business
Table 73. RxBio, Inc. Choroidal Neovascularization Drug Product and Services
Table 74. RxBio, Inc. Choroidal Neovascularization Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 75. Soligenix, Inc. Basic Information, Manufacturing Base and Competitors
Table 76. Soligenix, Inc. Major Business
Table 77. Soligenix, Inc. Choroidal Neovascularization Drug Product and Services
Table 78. Soligenix, Inc. Choroidal Neovascularization Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 79. Global Choroidal Neovascularization Drug Sales by Manufacturer (2019-2021e) & (K Pcs)
Table 80. Global Choroidal Neovascularization Drug Revenue by Manufacturer (2019-2021e) & (USD Million)
Table 81. Market Position of Manufacturers in Choroidal Neovascularization Drug, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2020
Table 82. Global Choroidal Neovascularization Drug Production Capacity by Company, (K Pcs): 2020 VS 2021
Table 83. Head Office and Choroidal Neovascularization Drug Production Site of Key Manufacturer
Table 84. Choroidal Neovascularization Drug New Entrant and Capacity Expansion Plans
Table 85. Choroidal Neovascularization Drug Mergers & Acquisitions in the Past Five Years
Table 86. Global Choroidal Neovascularization Drug Sales by Region (2016-2021e) & (K Pcs)
Table 87. Global Choroidal Neovascularization Drug Sales by Region (2021-2026) & (K Pcs)
Table 88. Global Choroidal Neovascularization Drug Revenue by Region (2016-2021e) & (USD Million)
Table 89. Global Choroidal Neovascularization Drug Revenue by Region (2021-2026) & (USD Million)
Table 90. Global Choroidal Neovascularization Drug Sales by Type (2016-2021e) & (K Pcs)
Table 91. Global Choroidal Neovascularization Drug Sales by Type (2021-2026) & (K Pcs)
Table 92. Global Choroidal Neovascularization Drug Revenue by Type (2016-2021e) & (USD Million)
Table 93. Global Choroidal Neovascularization Drug Revenue by Type (2021-2026) & (USD Million)
Table 94. Global Choroidal Neovascularization Drug Price by Type (2016-2021e) & (USD/Pcs)
Table 95. Global Choroidal Neovascularization Drug Price by Type (2021-2026) & (USD/Pcs)
Table 96. Global Choroidal Neovascularization Drug Sales by Application (2016-2021e) & (K Pcs)
Table 97. Global Choroidal Neovascularization Drug Sales by Application (2021-2026) & (K Pcs)
Table 98. Global Choroidal Neovascularization Drug Revenue by Application (2016-2021e) & (USD Million)
Table 99. Global Choroidal Neovascularization Drug Revenue by Application (2021-2026) & (USD Million)
Table 100. Global Choroidal Neovascularization Drug Price by Application (2016-2021e) & (USD/Pcs)
Table 101. Global Choroidal Neovascularization Drug Price by Application (2021-2026) & (USD/Pcs)
Table 102. North America Choroidal Neovascularization Drug Sales by Country (2016-2021e) & (K Pcs)
Table 103. North America Choroidal Neovascularization Drug Sales by Country (2021-2026) & (K Pcs)
Table 104. North America Choroidal Neovascularization Drug Revenue by Country (2016-2021e) & (USD Million)
Table 105. North America Choroidal Neovascularization Drug Revenue by Country (2021-2026) & (USD Million)
Table 106. North America Choroidal Neovascularization Drug Sales by Type (2016-2021e) & (K Pcs)
Table 107. North America Choroidal Neovascularization Drug Sales by Type (2021-2026) & (K Pcs)
Table 108. North America Choroidal Neovascularization Drug Sales by Application (2016-2021e) & (K Pcs)
Table 109. North America Choroidal Neovascularization Drug Sales by Application (2021-2026) & (K Pcs)
Table 110. Europe Choroidal Neovascularization Drug Sales by Country (2016-2021e) & (K Pcs)
Table 111. Europe Choroidal Neovascularization Drug Sales by Country (2021-2026) & (K Pcs)
Table 112. Europe Choroidal Neovascularization Drug Revenue by Country (2016-2021e) & (USD Million)
Table 113. Europe Choroidal Neovascularization Drug Revenue by Country (2021-2026) & (USD Million)
Table 114. Europe Choroidal Neovascularization Drug Sales by Type (2016-2021e) & (K Pcs)
Table 115. Europe Choroidal Neovascularization Drug Sales by Type (2021-2026) & (K Pcs)
Table 116. Europe Choroidal Neovascularization Drug Sales by Application (2016-2021e) & (K Pcs)
Table 117. Europe Choroidal Neovascularization Drug Sales by Application (2021-2026) & (K Pcs)
Table 118. Asia-Pacific Choroidal Neovascularization Drug Sales by Region (2016-2021e) & (K Pcs)
Table 119. Asia-Pacific Choroidal Neovascularization Drug Sales by Region (2021-2026) & (K Pcs)
Table 120. Asia-Pacific Choroidal Neovascularization Drug Revenue by Region (2016-2021e) & (USD Million)
Table 121. Asia-Pacific Choroidal Neovascularization Drug Revenue by Region (2021-2026) & (USD Million)
Table 122. Asia-Pacific Choroidal Neovascularization Drug Sales by Type (2016-2021e) & (K Pcs)
Table 123. Asia-Pacific Choroidal Neovascularization Drug Sales by Type (2021-2026) & (K Pcs)
Table 124. Asia-Pacific Choroidal Neovascularization Drug Sales by Application (2016-2021e) & (K Pcs)
Table 125. Asia-Pacific Choroidal Neovascularization Drug Sales by Application (2021-2026) & (K Pcs)
Table 126. South America Choroidal Neovascularization Drug Sales by Country (2016-2021e) & (K Pcs)
Table 127. South America Choroidal Neovascularization Drug Sales by Country (2021-2026) & (K Pcs)
Table 128. South America Choroidal Neovascularization Drug Revenue by Country (2016-2021e) & (USD Million)
Table 129. South America Choroidal Neovascularization Drug Revenue by Country (2021-2026) & (USD Million)
Table 130. South America Choroidal Neovascularization Drug Sales by Type (2016-2021e) & (K Pcs)
Table 131. South America Choroidal Neovascularization Drug Sales by Type (2021-2026) & (K Pcs)
Table 132. South America Choroidal Neovascularization Drug Sales by Application (2016-2021e) & (K Pcs)
Table 133. South America Choroidal Neovascularization Drug Sales by Application (2021-2026) & (K Pcs)
Table 134. Middle East & Africa Choroidal Neovascularization Drug Sales by Country (2016-2021e) & (K Pcs)
Table 135. Middle East & Africa Choroidal Neovascularization Drug Sales by Country (2021-2026) & (K Pcs)
Table 136. Middle East & Africa Choroidal Neovascularization Drug Revenue by Country (2016-2021e) & (USD Million)
Table 137. Middle East & Africa Choroidal Neovascularization Drug Revenue by Country (2021-2026) & (USD Million)
Table 138. Middle East & Africa Choroidal Neovascularization Drug Sales by Type (2016-2021e) & (K Pcs)
Table 139. Middle East & Africa Choroidal Neovascularization Drug Sales by Type (2021-2026) & (K Pcs)
Table 140. Middle East & Africa Choroidal Neovascularization Drug Sales by Application (2016-2021e) & (K Pcs)
Table 141. Middle East & Africa Choroidal Neovascularization Drug Sales by Application (2021-2026) & (K Pcs)
Table 142. Direct Channel Pros & Cons
Table 143. Indirect Channel Pros & Cons
Table 144. Choroidal Neovascularization Drug Typical Distributors
Table 145. Choroidal Neovascularization Drug Typical Customers
List of Figures
Figure 1. Choroidal Neovascularization Drug Picture
Figure 2. Global Choroidal Neovascularization Drug Sales Market Share by Type in 2020
Figure 3. AVMOC-001
Figure 4. BB-3
Figure 5. BBT-007
Figure 6. DG-3
Figure 7. Entolimod
Figure 8. EWA-001
Figure 9. Others
Figure 10. Global Choroidal Neovascularization Drug Sales Market Share by Application in 2020
Figure 11. Clinic
Figure 12. Hospital
Figure 13. Others
Figure 14. Global Choroidal Neovascularization Drug Market Size, (USD Million) & (K Pcs): 2020 VS 2021 VS 2026
Figure 15. Global Choroidal Neovascularization Drug Market Size and Forecast (2016-2026) & (USD Million)
Figure 16. Global Choroidal Neovascularization Drug Sales (2016-2026) & (K Pcs)
Figure 17. Global Choroidal Neovascularization Drug Price by Type (2016-2026) & (USD/Pcs)
Figure 18. Global Choroidal Neovascularization Drug Production Capacity (2016-2026) & (K Pcs)
Figure 19. Global Choroidal Neovascularization Drug Production Capacity by Geographic Region: 2020 VS 2021
Figure 20. Choroidal Neovascularization Drug Market Drivers
Figure 21. Choroidal Neovascularization Drug Market Restraints
Figure 22. Choroidal Neovascularization Drug Market Trends
Figure 23. Global Choroidal Neovascularization Drug Sales Market Share by Manufacturer in 2020
Figure 24. Global Choroidal Neovascularization Drug Revenue Market Share by Manufacturer in 2020
Figure 25. Choroidal Neovascularization Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 26. Top 3 Choroidal Neovascularization Drug Manufacturer (Revenue) Market Share in 2020
Figure 27. Top 6 Choroidal Neovascularization Drug Manufacturer (Revenue) Market Share in 2020
Figure 28. Global Choroidal Neovascularization Drug Sales Market Share by Region (2016-2026)
Figure 29. Global Choroidal Neovascularization Drug Revenue Market Share by Region (2016-2026)
Figure 30. North America Choroidal Neovascularization Drug Revenue (2016-2026) & (USD Million)
Figure 31. Europe Choroidal Neovascularization Drug Revenue (2016-2026) & (USD Million)
Figure 32. Asia-Pacific Choroidal Neovascularization Drug Revenue (2016-2026) & (USD Million)
Figure 33. South America Choroidal Neovascularization Drug Revenue (2016-2026) & (USD Million)
Figure 34. Middle East & Africa Choroidal Neovascularization Drug Revenue (2016-2026) & (USD Million)
Figure 35. Global Choroidal Neovascularization Drug Sales Market Share by Type (2016-2026)
Figure 36. Global Choroidal Neovascularization Drug Revenue Market Share by Type (2016-2026)
Figure 37. Global Choroidal Neovascularization Drug Price by Type (2016-2026) & (USD/Pcs)
Figure 38. Global Choroidal Neovascularization Drug Sales Market Share by Application (2016-2026)
Figure 39. Global Choroidal Neovascularization Drug Revenue Market Share by Application (2016-2026)
Figure 40. Global Choroidal Neovascularization Drug Price by Application (2016-2026) & (USD/Pcs)
Figure 41. North America Choroidal Neovascularization Drug Sales Market Share by Type (2016-2026)
Figure 42. North America Choroidal Neovascularization Drug Sales Market Share by Application (2016-2026)
Figure 43. North America Choroidal Neovascularization Drug Sales Market Share by Country (2016-2026)
Figure 44. North America Choroidal Neovascularization Drug Revenue Market Share by Country (2016-2026)
Figure 45. United States Choroidal Neovascularization Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 46. Canada Choroidal Neovascularization Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 47. Mexico Choroidal Neovascularization Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 48. Europe Choroidal Neovascularization Drug Sales Market Share by Type (2016-2026)
Figure 49. Europe Choroidal Neovascularization Drug Sales Market Share by Application (2016-2026)
Figure 50. Europe Choroidal Neovascularization Drug Sales Market Share by Country (2016-2026)
Figure 51. Europe Choroidal Neovascularization Drug Revenue Market Share by Country (2016-2026)
Figure 52. Germany Choroidal Neovascularization Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 53. France Choroidal Neovascularization Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 54. United Kingdom Choroidal Neovascularization Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 55. Russia Choroidal Neovascularization Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 56. Italy Choroidal Neovascularization Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 57. Asia-Pacific Choroidal Neovascularization Drug Sales Market Share by Region (2016-2026)
Figure 58. Asia-Pacific Choroidal Neovascularization Drug Sales Market Share by Application (2016-2026)
Figure 59. Asia-Pacific Choroidal Neovascularization Drug Sales Market Share by Region (2016-2026)
Figure 60. Asia-Pacific Choroidal Neovascularization Drug Revenue Market Share by Region (2016-2026)
Figure 61. China Choroidal Neovascularization Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 62. Japan Choroidal Neovascularization Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 63. Korea Choroidal Neovascularization Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 64. India Choroidal Neovascularization Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 65. Southeast Asia Choroidal Neovascularization Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 66. Australia Choroidal Neovascularization Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 67. South America Choroidal Neovascularization Drug Sales Market Share by Type (2016-2026)
Figure 68. South America Choroidal Neovascularization Drug Sales Market Share by Application (2016-2026)
Figure 69. South America Choroidal Neovascularization Drug Sales Market Share by Country (2016-2026)
Figure 70. South America Choroidal Neovascularization Drug Revenue Market Share by Country (2016-2026)
Figure 71. Brazil Choroidal Neovascularization Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 72. Argentina Choroidal Neovascularization Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 73. Middle East & Africa Choroidal Neovascularization Drug Sales Market Share by Type (2016-2026)
Figure 74. Middle East & Africa Choroidal Neovascularization Drug Sales Market Share by Application (2016-2026)
Figure 75. Middle East & Africa Choroidal Neovascularization Drug Sales Market Share by Country (2016-2026)
Figure 76. Middle East & Africa Choroidal Neovascularization Drug Revenue Market Share by Country (2016-2026)
Figure 77. Turkey Choroidal Neovascularization Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 78. Egypt Choroidal Neovascularization Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 79. Saudi Arabia Choroidal Neovascularization Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 80. South Africa Choroidal Neovascularization Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 81. Sales Channel: Direct Channel vs Indirect Channel
Figure 82. Methodology
Figure 83. Research Process and Data Source
世界のスニチニブ薬市場 2021：企業別、地域別、種類・用途別 The Sunitinib Drug market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, rec…- 世界のアンブリセンタン薬市場 2021：企業別、地域別、種類・用途別 The Ambrisentan Drug market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, r…
- 世界のNSCLC用標的薬物MEK阻害剤市場 2021：企業別、地域別、種類・用途別 The Targeted Drug MEK Inhibitors for NSCLC market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization…
- 世界のドルテグラビル/リルピビリン併用薬市場 2021：企業別、地域別、種類・用途別 The Dolutegravir/Rilpivirine Combination Drug market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimizat…
- 世界のコクシジオイデス症治療薬市場 2021：企業別、地域別、種類・用途別 The Coccidioidomycosis Drug market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulat…